Aug 18 2009 16: FECEIVED1

AUG 1 8 2009 SB/26 (02-09)
Approved for use through 03/31/2009. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE कुरात्म इत्य के प्रत्यक्षण का कुर स्वत्यक्षण का गाया है एक्स्यावस्था सम्बद्धकार स्वत्य किस्सा है। १९०० वर्ष का विक्रियों के प्रत्य के किस्सा का सम्बद्धकार के गाया है एक्स्यावस्था सम्बद्धकार स्वत्य किस्सा है। १९०० वर्ष के U.S. Perent and Trademark Office, U.S. Decay Men I OF Commission Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Döcket Number (Optional)
	NY-LUD 5253-US5-DIV
In re Application of: Thierry Boon-Falleur et al.	
Application No.: 08/819,669-Conf. #1995	
Filed: March 17, 1997	
TUMOR REJECTION, ANTIGEN PRECURSORS, TUMOR REJECTION ANTIGEN S AND USES THEREOF	
The owner*, _LUDWIG INSTITUTE FOR CANCER RESEARCH , of instant application hereby disclaims, except as provided below, the terminal part of the statutory instant application which would extend beyond the expiration date of the full statutory term of prior	100 percent interest in the term of any patent granted on the patent No. 5,843,448
as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.	
Further, the owner waives the right to separately enforce any granted on application 08/819,669 or any patent subject to re- examination proceedings, as well as U.S. Patent No. 5,843,448. The owner further states that any patent granted on application 09/819,669 or any patent subject to re-examination proceedings shall be enforced only for and during such period that the patent and the patent, or any patent granted on application 08/819,669, which formed the basis for the double patenting are not separately enforced.	
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:	
expires for failure to pay a maintenance fee; is held unenforceable; Is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is refssued; or	
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. X The undersigned is an attorney or agent of record. Reg. No. 30,946	
9 () 4	7/12/18
nolnative	1/13/07
Signature Signature	Date .
Norman D. Hanson Typed or printed name	
	(212) 318-3168
and the second of the second o	Telephone Number
X Charge Terminal disclaimer fee under 37 CFR 1.20(d) to Credit Card. PTO Form 2038 is attached.	
WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card Information and authorization on PTO-2038.	
Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	